ArticlePloS one2013
Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 77 citations in OpenAlex.
- Novel combined single dose anti-hepatitis C therapy: a pilot study.Scientific reports · 2021Trial
- Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.Scientific reports · 2019Trial
- Lipid peroxidation impacts orthoflavivirus infection in a virus-dependent manner.Cell death & disease · 2026Article
- The Role of Immunosenescence and Inflammaging in the Susceptibility of Older Adults to SARS-CoV-2 Infection.Current pharmaceutical biotechnology · 2026Review
- Metabolites profiling of Mimusops caffra leaf via multiplex GC-MS and UPLC-MS/MS approaches in relation to its antioxidant and anti-inflammatory activities.Scientific reports · 2025Article
- Phenolic Compounds inMolecules (Basel, Switzerland) · 2023Review
- Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study.Computers in biology and medicine · 2022Article
- Fighting coronaviruses with natural polyphenols.Biocatalysis and agricultural biotechnology · 2021Article
- Mechanisms Modified by (-)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies.Antioxidants (Basel, Switzerland) · 2021Review
- Health Benefits and Chemical Composition of Matcha Green Tea: A Review.Molecules (Basel, Switzerland) · 2020Review
- Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.Molecules (Basel, Switzerland) · 2020Review
- (-)-Epigallocatechin-3-Gallate Inhibits the Life Cycle of Pseudorabies VirusFrontiers in cellular and infection microbiology · 2020Article
- Discovery of 3-Arylquinoxaline Derivatives as Potential Anti-Dengue Virus Agents.International journal of molecular sciences · 2019Article
- A balanced game: chicken macrophage response to ALV-J infection.Veterinary research · 2019Article
- Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression.Scientific reports · 2018Article
- Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases.BioMed research international · 2018Review
- The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases.Oxidative medicine and cellular longevity · 2018Review
- Feline calicivirus- and murine norovirus-induced COX-2/PGE2 signaling pathway has proviral effects.PloS one · 2018Article
- Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- A Review of the Antiviral Role of Green Tea Catechins.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis C virus (HCV) infection is the leading risk factor for hepatocellular carcinoma (HCC) and chronic liver disease worldwide. Green tea, in addition to being consumed as a healthy beverage, contains phenolic catechins that have been used as medicinal substances. In the present study, we illustrated that the epicatechin isomers (+)-epicatechin and (-)-epicatechin concentration-dependently inhibited HCV replication at nontoxic concentrations by using in vitro cell-based HCV replicon and JFH-1 infectious systems. In addition to significantly suppressing virus-induced cyclooxygenase-2 (COX-2) expression, our results revealed that the anti-HCV activity of the epicatechin isomers occurred through the down-regulation of COX-2. Furthermore, both the epicatechin isomers additively inhibited HCV replication in combination with either interferon-α or viral enzyme inhibitors [2'-C-methylcytidine (NM-107) or telaprevir]. They also had prominent anti-inflammatory effects by inhibiting the gene expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and inducible nitrite oxide synthase as well as the COX-2 in viral protein-expressing hepatoma Huh-7 cells. Collectively, (+)-epicatechin and (-)-epicatechin may serve as therapeutic supplements for treating HCV-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.